2879-14-3

Usage

Uses

Used in Pharmaceutical Industry:
8-Phenyl-1H-purine-2,6(3H,7H)-dione is used as a reactant for the preparation of xanthine derivatives, which are known to act as adenosine A1 receptor antagonists. These antagonists have potential applications in the treatment of various conditions, such as neurological disorders, cardiovascular diseases, and certain types of cancer. 8-Phenyl-1H-purine-2,6(3H,7H)-dione's ability to form xanthine derivatives with antagonistic properties makes it a valuable component in the development of new pharmaceuticals.
Used in Chemical Research:
In addition to its pharmaceutical applications, 8-Phenyl-1H-purine-2,6(3H,7H)-dione can also be utilized in chemical research for the synthesis of various purine-based compounds. Its unique structure allows for further modification and functionalization, enabling the creation of novel molecules with potential applications in different industries, such as materials science, agrochemistry, and more.

Upstream product

• 32704-59-9 ethyl 5-amino-2-phenylimidazole-4-carboxylate 
• 57-13-6 urea 
• 82160-94-9 8-Phenyl-7-hydroxyxanthine 
• 100-52-7 benzaldehyde 
• 42965-55-9 5,6-diaminouracil sulfate 
• 3240-72-0 5,6-diaminouracil 
• 543-80-6 barium(II) acetate 
• 98-95-3 nitrobenzene 
• 98-88-4 benzoyl chloride 
• 3240-72-0 5,6-diaminouracil 
• 56-37-1 N-benzyl-N,N,N-triethylammonium chloride 
• 5350-41-4 trimethylbenzylammonium bromide 

Downstream Products

• 412918-55-9 2,6-dichloro-8-phenyl-9H-purine 

Relevant academic research and scientific papers

Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)-purine derivatives as cyclin-dependent kinase inhibitors. Part II

In this study, C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives were synthesized and their inhibitory effects on cyclin-dependent kinases (CDK2, 4) as well as their cytotoxicities were evaluated. The effects of substituents at the C-2, C-8, and N-9 positions of the substituted purine were investigated. Among the compounds tested, [6-(3-chloroanilino)-2-(2-hydroxymethyl-4-hydroxypyrrolidyl)- 9-isopropylpurine] (4h) was the most active inhibitor of CDK2 with IC50 of 0.3μM i.e. a two-fold increased inhibitory activity as compared to roscovitine. Results from structure-activity relationship studies should allow the design of more potent and selective CDK2 inhibitors, which may provide an effective therapy for cancer or other CDK-dependent diseases.

Synthesis of Paraxanthine Analogs (1,7-Disubstituted Xanthines) and Other Xanthines Unsubstituted at the 3-Position: Structure-Activity Relationships at Adenosine Receptors

Synthetic procedures for the preparation of various 3-unsubstituted xanthines, including paraxanthine analogs (1,7-disubstituted xanthines) and 1,8-disubstituted xanthines, were developed.Sylylation of 1-substituted xanthines followed by alkylation at the 7-position provides a facile route to paraxanthine analogs.Regioselective alkylation of tris(trimethylsilyl)-6-aminouracil provides 3-substituted 6-aminouracils, which are converted to 1,8-disubstituted xanthines by standard procedures.The ring closure of 3-substituted 5-cyclopentanecarboxamido- and 5-(benzoylamino)-6-aminouracils requires drastic reaction conditions.Affinity for brain A1 and A2 adenosine receptors was determined in binding assays for these and other xanthines with substituents in 1-, 3-, 7-, 8-, and 9-positions.Substitution at the 1-position was necessary for high affinity at adenosine receptors. 1,3-Disubstituted xanthines generally had higher affinity than 1,7-disubstituted xanthines. 1,8-Disubstituted xanthines had high affinity for adenosine receptors; some were highly selective for A1 receptors.